Observational studyJournal of perinatology : official journal of the California Perinatal Association2014
Parathyroid hormone as a marker for metabolic bone disease of prematurity.
Observational study in Journal of perinatology : official journal of the California Perinatal Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Continuous versus intermittent bolus infusion of calcium in preterm infants receiving total parenteral nutrition: a randomized blind clinical trial.BMC pediatrics · 2024Trial
- Monitored Supplementation of Vitamin D in Preterm Infants: A Randomized Controlled Trial.Nutrients · 2021Trial
- Metabolic bone disease of prematurity - what should we be measuring?Pediatric research · 2026Article
- Daily clinical markers in metabolic bone disease of prematurity.Pediatric research · 2026Article
- Umbilical Cord Biomarkers of Nutritional and Metabolic Status in Neonates with Intrauterine Growth Restriction.Journal of clinical medicine · 2026Review
- Biochemical markers for metabolic bone disease in preterm infants: insights from a structured Bone Health Programme in the Middle East.BMJ paediatrics open · 2025Article
- Fractures Associated with Metabolic Bone Disease in Extremely Preterm and Extremely Low Birth Weight Infants Before and After a Bone Health Program.Children (Basel, Switzerland) · 2025Article
- Metabolic bone disease in extremely preterm infants: incidence, risk factors, and outcomes from a structured bone health program.Frontiers in pediatrics · 2025Article
- A Prospective Study of Nephrocalcinosis in Very Preterm Infants: Incidence, Risk Factors and Vitamin D Intake in the First Month.Medicina (Kaunas, Lithuania) · 2024Observational
- Effect of early preventive supplementation with calcium and phosphorus on metabolic bone disease in premature infants.BMC pediatrics · 2024Article
- Incidence, Risk Factors and Prediction of Secondary Hyperparathyroidism in Preterm Neonates under 32 Weeks' Gestational Age.Nutrients · 2022Article
- Expert consensus on clinical management of metabolic bone disease of prematurity (2021).Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- [Risk factors for metabolic bone disease of prematurity in very/extremely low birth weight infants: a multicenter investigation in China].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- Metabolic bone disease of prematurity-National survey of current neonatal and paediatric endocrine approaches.Acta paediatrica (Oslo, Norway : 1992) · 2021Article
- Effect on metabolic bone disease markers in the neonatal intensive care unit with implementation of a practice guideline.Journal of perinatology : official journal of the California Perinatal Association · 2020Article
- Association of Protein and Vitamin D Intake With Biochemical Markers in Premature Osteopenic Infants: A Case-Control Study.Frontiers in pediatrics · 2020Article
- Evaluating Bone Health in Egyptian Children with Forearm Fractures: A Case Control Study.International journal of pediatrics · 2016Article
- Calcitriol treatment in metabolic bone disease of prematurity with elevated parathyroid hormone: A preliminary study.Journal of clinical & translational endocrinology · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare parathyroid hormone to alkaline phosphatase as a serologic marker for metabolic bone disease (MBD) in preterm infants. STUDY
designAn 18-month prospective observational study in neonates with birth weight < 1250 g. Simultaneous serum parathyroid hormone (PTH), alkaline phosphatase (ALP), calcium (Ca) and phosphorus (P) were measured at scheduled intervals during hospitalization. At 6 weeks of age, MBD was evaluated using knee radiographs. Comparisons were analyzed using multivariate logistic regression, receiver operating characteristic (ROC) curves, χ² and Student t-test.
resultFourty-nine infants were included in the study: 7 with severe and 42 with mild MBD. Using ROC curves, at 660 U l⁻¹ ALP had a sensitivity of 29% and specificity of 93% for severe MBD, while a cutoff point of 180 pg ml⁻¹ gave PTH a sensitivity of 71% and specificity of 88%. Infants with severe bone disease had a lower birth weight, 21-day serum P, an increased use of glucocorticoids and caffeine, and more likely to have major neonatal morbidities.
conclusionPTH is an early marker with better sensitivity than ALP in screening for MBD. At 3 weeks chronologic age, a PTH level > 180 mg dl⁻¹ or a P level <4.6 pg ml⁻¹ yielded a sensitivity of 100% and specificity of 94% for severe MBD [corrected].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.